Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01263275




Registration number
NCT01263275
Ethics application status
Date submitted
7/12/2010
Date registered
20/12/2010
Date last updated
17/09/2015

Titles & IDs
Public title
Trial of Transcranial Direct Current Stimulation (tDCS) for Depression
Scientific title
Open Pilot Trial of Transcranial Direct Current Stimulation (tDCS) for Depression.
Secondary ID [1] 0 0
10368
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Major Depression 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - tDCS (Eldith DC-Stimulator (CE certified))

Experimental: Active tDCS -


Treatment: Devices: tDCS (Eldith DC-Stimulator (CE certified))
Each tDCS session lasting continuously for 20 minutes at 2 mA
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Montgomery Asberg Depression Rating Scale for Depression (MADRS).
Timepoint [1] 0 0
6 months

Eligibility
Key inclusion criteria
1. Subject meets criteria for a DSM-IV Major Depressive Episode.

2. Total MADRS score =20.

3. Subject has not responded to tDCS given with a standard montage OR subject is unable
to receive tDCS with standard montage - for example, due to skin rash etc at site of
electrode placement for standard montage.
Minimum age
18 Years
Maximum age
90 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Diagnosis (as defined by DSM-IV) of: any psychotic disorder (lifetime); eating
disorder (current or within the past year); obsessive compulsive disorder (lifetime);
post-traumatic stress disorder (current or within the past year); mental retardation.

2. History of drug or alcohol abuse or dependence (as per DSM-IV criteria) within the
last 3 months (except nicotine and caffeine).

3. Inadequate response to ECT in the current episode of depression.

4. Subject is on regular benzodiazepine medication which it is not clinically appropriate
to discontinue.

5. Subject requires a rapid clinical response due to inanition, psychosis or high suicide
risk.

6. Neurological disorder or insult, e.g., recent stroke (CVA), which places subject at
risk of seizure or neuronal damage with tDCS.

7. Subject has metal in the cranium, skull defects, or skin lesions on scalp (cuts,
abrasions, rash) at proposed electrode sites.

8. Female subject who is pregnant.

9. Participants who are not fluent in English will not be included in the trial for
safety reasons: a) It is usually not possible to have an interpreter reliably
available every weekday for up to 4 weeks and it is not safe to give tDCS to a subject
who cannot tell us immediately of any side effects; b) As this is a novel treatment,
the study involves detailed neuropsychological testing for safety reasons. This
testing cannot be effectively or validly completed by someone who is not fluent in
English. Note that translation of the proposed tests into English has not been
validated and that we cannot be confident that neuropsychological impairment would be
detected using this method.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2015
Sample size
Target
Accrual to date
Final
3
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Black Dog Institute - Randwick, Sydney
Recruitment postcode(s) [1] 0 0
2031 - Randwick, Sydney

Funding & Sponsors
Primary sponsor type
Other
Name
The University of New South Wales
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Among antidepressant treatments, ECT stands as the most effective in treating acute
depression. However, patient concerns with the cognitive side effects of ECT have encouraged
the development of new and more focal forms of brain stimulation such as transcranial Direct
Current Stimulation (tDCS). However, not all patients may respond to this treatment in the
way that it is currently administered and this has raised interest in finding alternative,
possibly more optimal ways of administering tDCS. This study will investigate whether tDCS
stimulation using an alternative electrode montage has antidepressant effects.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01263275
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Colleen Loo, MBBS, FRANZCP, MD
Address 0 0
School of Psychiatry, University of New South Wales
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01263275